Pralidoxime Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 g/10 mL
Reference Brands: Protopam Chloride (USA)
Category:
Critical Care
Pralidoxime is available in Injection
and strengths such as 1 g/10 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pralidoxime is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pralidoxime can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pralidoxime, also known as 2-PAM (2-pyridine aldoxime methyl chloride), is a critical antidote used in the management and treatment of organophosphate poisoning. Belonging to the oxime class of drugs, pralidoxime works by reactivating acetylcholinesterase that has been inactivated by organophosphate compounds, thereby restoring normal nerve function and alleviating the toxic effects of cholinergic overstimulation. It is commonly administered in combination with atropine and, when needed, benzodiazepines such as diazepam or midazolam to manage seizures or severe symptoms.
Pralidoxime is available as chloride or iodide salts and is supplied as a sterile injectable solution for intravenous or intramuscular use. It is particularly valuable in cases of poisoning with organophosphate-based pesticides or nerve agents, where rapid intervention is essential to prevent life-threatening complications. Clinical use requires careful dosing based on the severity of exposure and patient condition, with monitoring of vital signs and cholinesterase activity to guide therapy.
Due to its effectiveness and rapid action, pralidoxime is an essential component of emergency and critical care protocols for organophosphate toxicity. It has a well-characterized safety profile, though adverse effects such as hypertension, tachycardia, and mild neuromuscular symptoms may occur if administered too rapidly. Its targeted mechanism and role in multidisciplinary care make it indispensable in managing acute organophosphate poisoning.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing